文献速递胸部肿瘤放疗放疗物理与技术

Ⅱ-Ⅲ期非小细胞肺癌同步整合加量放疗联合化疗的Ⅰ期研究

Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-11-03

最高SIB剂量光子组72 Gy、质子组78 Gy(CGE);72 Gy组9例中1例≥3级食管炎,78 Gy质子组6例中2例≥3级肺炎(含1例5级)。推荐72 Gy(CGE)作为后续随机Ⅱ期研究的最高SIB剂量。

要点

  • SIB最高剂量光子组72 Gy、质子组78 Gy(CGE),靶区60 Gy/30次。
  • 72 Gy组9例中1例≥3级食管炎,78 Gy质子组6例中2例≥3级肺炎。
  • 中位随访25个月仅1例边缘复发,推荐72 Gy(CGE)进入Ⅱ期。

核心结论

  • 推荐同步整合加量剂量72 Gy(CGE)作为计划开展的随机Ⅱ期研究的最高SIB剂量。

研究设计与样本

  • 前瞻性Ⅰ/Ⅱ期研究的Ⅰ期部分,纳入病理证实的不可切除Ⅱ-ⅢB期或术后复发非小细胞肺癌患者。
  • 放疗采用影像引导调强光子放疗或调强质子治疗,均联合同步整合加量,靶区处方60 Gy(CGE)/30次。
  • 有治疗机空位时患者随机分入IMRT组或IMPT组,否则按空位非随机分配。

主要发现

  • SIB最高剂量在IMRT组为72 Gy,在IMPT组为78 Gy(CGE)。
  • 9例(IMRT 6例、IMPT 3例)接受72 Gy(CGE) SIB剂量,生物有效剂量为89.3 Gy(CGE)。
  • 6例(均为IMPT)接受78 Gy(CGE) SIB剂量,生物有效剂量为98.3 Gy(CGE)。
  • 72 Gy(CGE)组9例中1例出现剂量限制性≥3级毒性(食管炎)。
  • 78 Gy(CGE) IMPT组6例中2例出现≥3级肺炎:1例3级于治疗后3个月,1例5级(可能与治疗相关)于治疗后2个月。

关键数值与推荐

  • 靶区处方剂量维持60 Gy(CGE)/30次,SIB体积为内大体肿瘤体积外放5 mm。
  • IMRT组SIB最高剂量72 Gy,IMPT组SIB最高剂量78 Gy(CGE)。
  • 72 Gy(CGE) SIB的生物有效剂量为89.3 Gy(CGE),78 Gy(CGE) SIB的生物有效剂量为98.3 Gy(CGE)。
  • 剂量限制性毒性定义为≥3级毒性,72 Gy(CGE)组发生1例食管炎。

临床怎么用

  • 对接受同步放化疗的Ⅱ-ⅢB期非小细胞肺癌患者,SIB加量至72 Gy(CGE)总体可耐受。
  • 采用IMPT加量至78 Gy(CGE)时需警惕≥3级肺炎,包括可能致命的5级事件。
  • 后续随机Ⅱ期研究应采用72 Gy(CGE)作为最高SIB剂量。

局限性

  • IMRT与IMPT分组受治疗机空位影响,部分患者为非随机分配。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To establish, in the phase 1 portion of a prospective phase 1/2 study, the maximum tolerated dose of image guided intensity modulated radiation therapy (IMRT) or proton therapy (IMPT), both with a simultaneous integrated boost (SIB), for patients with stage II to IIIB non-small cell lung cancer receiving concurrent chemoradiation therapy. METHODS AND MATERIALS: Patients had pathologically proven non-small cell lung cancer, either unresectable stage II to IIIB disease or recurrent disease after surgical resection, and could tolerate concurrent chemoradiation. Radiation doses were selectively escalated to the SIB volume (internal gross tumor volume + 5-mm margin), and the dose to the planning target volume (internal gross tumor volume + 8-mm margin for clinical target volume + 5 mm) was kept at 60 Gy [cobalt gray equivalent (CGE)] over 30 fractions. Patients were randomized between the IMRT and IMPT groups if slots were available on the treatment machines for both groups. Otherwise, patients were allocated to IMRT or IMPT, whichever had an open treatment slot on the machine without randomization. RESULTS: Fifteen patients (6 IMRT, 9 IMPT) were enrolled. The highest doses to the SIB were 72 Gy in the IMRT group and 78 Gy(CGE) in the IMPT group. Nine patients (6 IMRT, 3 IMPT) received an SIB dose of 72 Gy(CGE) [biologically effective dose = 89.3 Gy(CGE)], and 6 patients (IMPT) received an SIB dose of 78 Gy(CGE) [biologically effective dose = 98.3 Gy(CGE)]. Dose-limiting (grade ≥3) toxicity (esophagitis) developed in 1 of the 9 patients given 72 Gy(CGE) SIB. Grade ≥3 pneumonitis developed in 2 of the 6 patients treated to 78 Gy(CGE) IMPT SIB: 1 (grade 3) at 3 months after treatment and the other (grade 5, possibly related to treatment) at 2 months after treatment. Only 1 patient developed a marginal tumor recurrence with a median follow-up of 25 months (range, 4.3-47.4 months). CONCLUSIONS: We recommend that an SIB dose of 72 Gy(CGE) be used as the highest SIB dose for the planned randomized phase 2 study.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Jeter MD, Gomez D, Nguyen QN, et al. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study. Int J Radiat Oncol Biol Phys. 2017. PMID: 29248169. doi:10.1016/j.ijrobp.2017.10.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。